Collectively, these data demonstrate the dependency of PPL cancer cell growth on DNA hypomethylation, advocating for the therapeutic strategy of targeting this epigenetic vulnerability through both pharmacological inhibition of TETs and supplementation of SAM to combat AR-independent prostate cancer (Fig. 6l). This evidence concerns the gene AR and prostate cancer.